Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label ...

Despite a significant net loss, Compass Pathways PLC (CMPS) secures financing to advance key clinical trials and strengthen its financial position.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

In the second episode of The Deep End, listeners hear what it’s like to live with severe depression and the backstory of an experimental treatment.

St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with ...

A new non-invasive treatment for depression, which has been shown to deliver remission for one third of its patients, is to ...